Jena, December 11, 2008 SIRS-Lab is pleased to announce the appointment of Ania Mitan as Executive Vice President Commercial.
This expansion of the senior management accelerates the routine implementation of SIRS-Lab's breakthrough diagnostic suite for sepsis. In her capacity, Ania Mitan will be responsible for commercial planning and execution as well as business development.
She brings 15 years of pharmaceutical industry experience in senior management positions and with exposure to the worldwide markets. Most recently, Mrs. Mitan was European Marketing Director of Eli Lilly with an outstanding track record in the clinical implementation and commercialization of sepsis pharmaceuticals.
PD Dr Stefan Russwurm, CEO of SIRS-Lab, stated: "Ania Mitan shows an impressive track record and we are delighted that she has now joined our team here at SIRS-Lab. Her motivational leadership strengthens our executive management through a significant reservoir of knowledge and experience in the areas of product commercialization and business development."
Ania Mitan has stated, about her decision to join SIRS-Lab, that "I am very excited to join SIRS-Lab in its most dynamic phase. We share the same vision of reinventing clinicians' views on sepsis diagnostics. SIRS-Lab's unique solutions precisely address the major questions in sepsis treatment."
SIRS-Lab, a leading molecular diagnostic company dealing with the field of life-threatening infections, is currently expanding its marketing and sales portfolio, by recruiting key experts to accelerate the implementation of its sepsis diagnostic suite into clinical routine. VYOO, the cutting-edge test for the rapid and reliable identification of sepsis pathogens, has been available for purchase since December 2007. The first-in-class test SIQNATURE, used for the early prediction and monitoring of system infection, is now accessible for selected scientific experts and will be fully commercialized in 2009.
Sepsis, a main cause of death
Sepsis is a life-threatening systemic infection and one of the main causes of death in hospitals worldwide. Per year, approximately 2 million people suffer from sepsis in industrial countries alone. With an average mortality rate of 50%, the disease is one of the most unmet medical needs and a major burden on healthcare resources.
About SIRS-Lab GmbH
Located in Jena, Germany, SIRS-Lab is a molecular diagnostic company which develops and commercializes unique and innovative products to identify and monitor life-threatening infections such as sepsis, one of the major causes of death in hospitals. With its diagnostic suite consisting of VYOO and SIQNATURE, SIRS-Lab´s molecular diagnostic portfolio meets the currently unmet medical needs of fast and reliable identification and monitoring of sepsis. Created as a spin-off of the University Clinic of Jena, SIRS-Lab was founded in 2000 by S. Russwurm, K. Reinhart, E. Straube, and H.-P. Saluz, and has currently about 50 employees.